SYRS

Syros Pharmaceuticals, Inc. Common Stock
SYRS

Overview Fund Activity
Delisted

SYRS was delisted on the 19th of March, 2025.

Back to rankings

68 hedge funds and large institutions have $321M invested in Syros Pharmaceuticals, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 14 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
68
Holders Change
+3
Holders Change %
+4.62%
% of All Funds
1.48%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
14
Increased
35
Reduced
14
Closed
9
Calls
$931K
Puts
$3K
Net Calls
+$928K
Net Calls Change
+$681K

Top Buyers

1
NAMA
Nikko Asset Management Americas
New York
+$21.3M
2
RG
Redmile Group
California
+$18.3M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$10.1M
4
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
+$8.38M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$7.99M

Top Sellers

1
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
-$833K
2
WCM
Wedge Capital Management
North Carolina
-$762K
3
AA
ALPS Advisors
Colorado
-$743K
4
Millennium Management
Millennium Management
New York
-$637K
5
BCM
Bridgeway Capital Management
Texas
-$370K
Name Holding Trade Value Shares
Change 		Shares
Change %
MAM
76
Meeder Asset Management
Ohio
– -$3K -28 Closed
1 2 3
4